← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Other immunostimulants
poly ICLC
L03AX08
Forms & Strengths
- Injectable solution: 2 mg/mL
Adult Dosing
- Malignant glioma: 10 to 50 mcg/kg intramuscularly or subcutaneously twice weekly
- Dosing regimens vary significantly based on specific clinical trial protocols
Pediatric Dosing
- Safety and efficacy in pediatric patients not fully established
- Investigational dosing in pediatric brain tumors typically ranges from 10 to 20 mcg/kg IM/SC biweekly under clinical trial protocols
Indications
- Investigational immunomodulator and antiviral
- Studied as an adjunct treatment for malignant gliomas (e.g., glioblastoma multiforme)
- Investigated as a vaccine adjuvant and antiviral agent
Mechanism of Action
- Synthetic double-stranded RNA complex of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose
- Acts as a potent Toll-like receptor 3 (TLR3) agonist and melanoma differentiation-associated protein 5 (MDA5) activator
- Induces the production of type I interferons (IFN-alpha and IFN-beta) and other proinflammatory cytokines, enhancing innate and adaptive cellular immunity
Contraindications
- Hypersensitivity to poly ICLC, poly-L-lysine, or carboxymethylcellulose
- Severe pre-existing autoimmune disorders where immune stimulation is hazardous
Adverse Reactions
- Flu-like symptoms (fever, chills, myalgia, fatigue)
- Injection site reactions (pain, erythema, induration)
- Headache and dizziness
- Transient transaminase elevation
- Leukopenia and thrombocytopenia at higher doses
Drug Interactions
- Immunosuppressants (corticosteroids, chemotherapy): May blunt the immunomodulatory efficacy of poly ICLC
- Hepatotoxic drugs: Potential for additive hepatotoxicity with concurrent use
- Anticoagulants: Increased risk of hematoma formation at intramuscular injection sites
Curated Content: Needs Vetting Before Put to Clinical Use